Compare GOLF & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOLF | ERAS |
|---|---|---|
| Founded | 1910 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.5B |
| IPO Year | 2016 | 2021 |
| Metric | GOLF | ERAS |
|---|---|---|
| Price | $85.62 | $10.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $83.67 | $14.25 |
| AVG Volume (30 Days) | 320.6K | ★ 8.6M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ 1.36 | N/A |
| Revenue | ★ $1,633,721,000.00 | N/A |
| Revenue This Year | $5.76 | N/A |
| Revenue Next Year | $2.44 | N/A |
| P/E Ratio | $63.16 | ★ N/A |
| Revenue Growth | ★ 4.71 | N/A |
| 52 Week Low | $67.14 | $1.06 |
| 52 Week High | $104.81 | $24.28 |
| Indicator | GOLF | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 36.35 | 36.23 |
| Support Level | $78.60 | $2.07 |
| Resistance Level | $86.07 | $16.14 |
| Average True Range (ATR) | 3.30 | 0.88 |
| MACD | -1.01 | -0.21 |
| Stochastic Oscillator | 11.64 | 59.45 |
Acushnet Holdings Corp is engaged in the design, development, manufacture, and distribution of golf products. Its product category includes golf balls, golf shoes, golf clubs, wedges, putters, golf gloves, golf gear and golf wear, and others. These products are offered through different brands such as Titleist, FootJoy, Scotty Cemeron, Vokey Design, Pinnacle, KJUS, and others. The company's reportable segments are Titleist golf equipment, FootJoy golf wear, and Gofl gear. A majority of its revenue is generated by the Titleist golf equipment segment. Geographically, the company generates maximum revenue from the United States, followed by Europe, Middle East and Asia (EMEA), Japan, Korea, and the Rest of the world.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.